## SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of

# 2 Immunodeficiency

1

- 3 Yijia Li\*123, Manish C. Choudhary\*1, James Regan\*1, Julie Boucau4, Anusha Nathan45,
- 4 Tessa Speidel<sup>6</sup>, May Yee Liew<sup>2</sup>, Gregory E. Edelstein<sup>1</sup>, Yumeko Kawano<sup>1</sup>, Rockib Uddin<sup>2</sup>,
- 5 Rinki Deo<sup>1</sup>, Caitlin Marino<sup>4</sup>, Matthew A. Getz<sup>4</sup>, Zahra Reynold<sup>2</sup>, Mamadou Barry<sup>2</sup>, Rebecca F.
- 6 Gilbert<sup>2</sup>, Dessie Tien<sup>2</sup>, Shruti Sagar<sup>2</sup>, Tammy D. Vyas<sup>2</sup>, James P. Flynn<sup>1</sup>, Sarah P.
- 7 Hammond<sup>2</sup>, Lewis A. Novack<sup>1</sup>, Bina Choi<sup>1</sup>, Manuela Cernadas<sup>1</sup>, Zachary S. Wallace<sup>2</sup>, Jeffrey
- 8 A. Sparks<sup>1</sup>, Jatin M. Vyas<sup>2</sup>, Michael S. Seaman<sup>6</sup>, Gaurav D. Gaiha<sup>2</sup>, Mark J. Siedner<sup>#2</sup>,
- 9 Amy K. Barczak<sup>#2 4</sup>, Jacob E. Lemieux<sup>#2 7</sup>, Jonathan Z. Li<sup>#1</sup>
- 11 Affiliations:

10

- 1. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 13 2. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 14 3. University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 4. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
- 16 5. Program in Health Sciences and Technology, Harvard Medical School and Massachusetts Institute of
- 17 Technology, Boston, MA 02115, USA
- 18 6. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical
- 19 School, Boston, MA, USA
- 7. Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 22 \*, # Equal contribution
- 24 Funding:

21

- 25 This work was supported by the National Institutes of Health (U19 Al110818), the Massachusetts
- 26 Consortium for Pathogen Readiness SARS-CoV-2 Variants Program and the Massachusetts General

Hospital Department of Medicine. Drs. JA Sparks and ZS Wallace are supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR080659). Dr. JA Sparks is also supported by the Llura Gund Award funded by the Gordon and Llura Gund Foundation. Dr. GD Gaiha is supported by the NIH (DP2AI154421, R01AI176533 and DP1DA058476), the Bill and Melinda Gates Foundation, Burroughs Wellcome Career Award for Medical Scientists and Howard Goodman Fellowship. Dr. JZ Li was also supported by a grant from Merck. Dr. Y Li was supported by Rustbelt CFAR (Case Western Reserve University/University Hospitals Cleveland Medical Center and University of Pittsburgh, P30 Al036219). The BSL3 laboratory where viral culture work was performed is supported by the Harvard CFAR (P30 Al060354). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.

### **Abstract**

Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for prolonged SARS-CoV-2 infection, but the immune defects that predispose to persistent COVID-19 remain incompletely understood. In this study, we performed detailed viro-immunologic analyses of a prospective cohort of participants with COVID-19. The median time to nasal viral RNA and culture clearance in the severe hematologic malignancy/transplant group (S-HT) were 72 and 21 days, respectively, which were significantly longer than clearance rates in the severe autoimmune/B-cell deficient (S-A), non-severe, and non-immunocompromised groups (P<0.001). Participants who were severely immunocompromised had greater SARS-CoV-2 evolution and higher risk of developing antiviral treatment resistance. Both S-HT and S-A participants had diminished SARS-CoV-2-specific humoral, while only the S-HT group had reduced T cell-mediated responses. This highlights the varied risk of persistent COVID-19 across immunosuppressive conditions and suggests that suppression of both B and T cell responses results in the highest contributing risk of persistent infection.

### Introduction

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Coronavirus Disease 2019 (COVID-19) vaccinations have drastically transformed the landscape of the COVID-19 pandemic by offering significant protection against infection acquisition, and severe diseases<sup>1,2</sup>, and ultimately have averted tens of millions of deaths<sup>3</sup>. Unfortunately, not all individuals respond to vaccination equally well, and immunocompromised individuals can have poor vaccine responses<sup>4,5</sup> and worse COVID-19-related outcomes<sup>6,7</sup>. Each new variant of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) brings risks of resistance to current treatments, particularly targeted antibody therapies<sup>8,9</sup>, resistance to vaccine-induced and naturally acquired immunity<sup>9,10</sup>, and increased transmissibility<sup>10</sup>. Immunocompromised individuals have been observed to harbor detectable SARS-CoV-2 virus for longer than nonimmunocompromised individuals<sup>11-13</sup>. Such individuals represent a potential origin of novel SARS-CoV-2 variants as persistent infection has been associated with accelerated viral evolution<sup>11,13</sup>. However, the immunocompromised state is composed of a range of conditions and immune defects. These defects that predispose to persistent COVID-19 remain undercharacterized. While there have been a number of case reports of persistent COVID-19 in immunosuppressed individuals<sup>11-16</sup> showing excessively prolonged viral shedding, persistent disease, and intra-host virological genetic diversity, there remains a need for larger scale studies with a comprehensive virologic and immunologic characterization to better elucidate the immunologic risk factors for and mechanisms of persistent infection. To this end, we hereby present a detailed longitudinal virological and immunological analysis of a cohort of immunocompromised and non-immunocompromised participants with SARS-CoV-2 infection with the goal of characterizing the virologic spectrum of persistent infection and exploring the immunologic determinants that predispose to its occurrence.

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

Results **Participant Characteristics** Fifty-six immunocompromised participants and 184 non-immunocompromised participants enrolled in the POSITIVES longitudinal cohort study were included in this analysis <sup>17-19</sup>. Demographic information and key viral characteristics are shown in Table 1. Immunocompromised participants were significantly older than non-immunocompromised controls (median 55 vs 46 years, P=0.001), and more likely to receive monoclonal antibody (mAb) and/or antiviral treatment against SARS-CoV-2. The two groups had comparable sex, race, and ethnicity profiles and a similar median time from symptom onset/first positive COVID-19 test to enrollment (5 vs 4 days). We further subdivided immunocompromised participants into the severe hematologic-oncology/transplant (S-HT, n=12), severe autoimmune/B-cell deficient (S-A, n=13) and non-severe (NS, n=31) groups (refer to Supplementary Tables 1 and 2 for detailed categorization). Three participants died due to severe COVID-19 or COVID-19 related complications, all of whom were in the immunocompromised sub-group (S-HT and S-A). Delayed Viral Clearance in Hematologic Oncology and Transplant Participants We first aimed to characterize viral dynamics in the upper respiratory tract in participants with different categories of immunocompromising conditions. Immunocompromised and nonimmunocompromised participants had similar peak vRNA levels (5.1, 5.1, 4.9, and 5.7 log<sub>10</sub> SARS-CoV-2 copies/ml in S-HT, S-A, NS and non-immunocompromised groups, P=0.5). However, the rates of nasal vRNA decay were significantly different between the immunocompromising categories, with the S-HT group demonstrating significantly slower viral clearance compared to other groups (Fig. 1a and 1b). Median time to nasal vRNA clearance in the S-HT group was 72 days (95% confidence interval [CI] 5, not available [NA]) compared to 7 (6, NA) days for the S-A, 11 (8, 16) days for the NS and 11 (10, 12) days for the non-

immunocompromised group (Fig. 1b, log-rank P=0.005). Similarly, the S-HT group experienced

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

significant delay in the clearance of culturable virus (Fig. 1c and 1d). Median time to viral culture clearance in the S-HT group was 21 days (95%CI 5, NA) compared to 6.5 (5, NA) days for the S-A group, 6 days (5, 7) for the NS group and 7 days (6, 7) for the nonimmunocompromised group (Fig. 1d, log-rank P=0.0007, Fig. 1d). After 30 days from symptom onset or first positive test, 50%, 15%, and 6.5% of participants from S-HT, S-A and NS groups had detectable vRNA, compared to 0% in non-immunocompromised group (P<0.0001, Extended Data Fig. 1a). In addition, 33% of S-HT and 8.3% of S-A participants still had culturable virus, compared to 0% in the NS and non-immunocompromised groups after 30 days (P<0.0001, Extended Data Fig. 1b). Compared to the non-immunocompromised group, the S-HT group was significantly associated with delayed vRNA clearance (adjusted hazard ratio [aHR] for viral clearance, 0.35, 95% CI 0.13-0.91, P=0.03) and culturable virus clearance (aHR 0.34 for viral clearance, 95% CI 0.15-0.76, P=0.009), after adjusting for demographics, number of vaccinations and antiviral use (Table 2). Increased Viral Evolution and Genetic Diversity in Immunocompromised Participants We used gene-specific next-generation sequencing approach to quantify the number of unique intra-host single-nucleotide variants (iSNVs) in the S gene present at >3% frequency within each sample. This analysis was limited to participants with a viral genome available both at baseline and at least one follow-up timepoint. Severely immunocompromised (S-HT and S-A) participants harbored a greater number of iSNVs over time compared to NS and nonimmunocompromised group participants, although these comparisons did not reach statistic significance (Fig. 2a). To evaluate viral diversity, we calculated the average pairwise distance both at the nucleotide and at the amino-acid level. Nucleotide average pairwise distance was significantly higher in the severe immunocompromised (S-HT and S-A) group compared to either non-severe (4.0E-4 vs 8.2E-5, P<0.001 Dunn's test with Benjamini-Hochberg adjustment) or non-immunocompromised groups (4.0E-4 vs 2.3E-5, P<0.001, Fig. 2b). Similar results were

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

obtained when the average pairwise distances were calculated for amino acids (Extended Data Fig. 2a). Among participants with longitudinal sequences, 39% of the participants in immunocompromised group versus 12% in the non-immunocompromised group had evidence of viral nucleotide changes (Fisher's exact P<0.001, Fig. 2c). These nucleotide changes were distributed across the entire length of the S gene (Fig. 2d). Increased Risk of Treatment-Emergent Resistance to Anti-SARS-CoV-2 Monoclonal **Antibody Therapy** Deep sequencing analysis of Spike gene was carried out to evaluate the dynamics of mutation emergence in the presence of mAb treatment as earlier reports have shown evidence of mAb resistance emergence both in immunocompromised and non-immunocompromised participants<sup>13,20-29</sup>. In total, 34 participants across different study groups received mAb therapy, 10 in S-HT, 9 in S-A, 5 in NS, and 10 in non-immunocompromised groups (Details in Supplemental Table 3). Of these, we were able to evaluate the risk of resistance emergence in a subset of participants for whom sequences were available at both baseline and at least one follow-up time point. Five out of nine (56%) severely immunocompromised participants (S-HT and S-A) developed mAb-specific resistance mutations (Extended data Fig. 2b). This was a significantly higher rate than that found in the non-severe or non-immunocompromised groups (0/11 [0%] combined, Fisher's exact P=0.008) (Fig 2e). Suboptimal Humoral Response in Severely Immunocompromised Participants We next characterized the antibody response in immunocompromised and nonimmunocompromised participants. In participants whose serum sample was available (n=94), including those who had previously received monoclonal antibodies, we found no significant difference in nAb titers between the different immunocompromised and nonimmunocompromised groups at early and later sampling time points, although this analysis may

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

have been limited due to individuals who received anti-SARS-CoV-2 monoclonal antibody infusion before sample collection (either therapeutic or pre-exposure prophylaxis) (Fig. 3a and 3b). The non-immunocompromised group had a significant increase in anti-ancestral and antivariant spike nAb levels during follow-up, whereas we did not observe a significant increase in antibody levels in the immunocompromised group (Fig. 3a and 3b). However, after excluding individuals with exposure to mAb therapies, the severe immunocompromised group showed no significant changes in either anti-ancestral or anti-variant Spike nAb levels, while the non-severe immunocompromised group demonstrated a moderate increase and the nonimmunocompromised group demonstrated the greatest increase in nAb levels, plateauing at day 25-30 (Fig. 3c and d). In a generalized estimating equation (GEE) model adjusted for factors associated with nAb levels, severely immunocompromised participants were only able to mount 0.18-fold (approximately 5-fold lower) of the anti-ancestral Spike antibody (95% CI 0.05-0.60) and 0.08fold (approximately 12-fold lower) of the anti-variant Spike antibody (95% CI 0.03-0.22) compared to non-immunocompromised participants (Extended Fig. 3a, b). Non-severe immunocompromised status was not associated with significant differences in nAb changes from acute to post-infection, compared to non-immunocompromised group. In the whole cohort, each dose of vaccinations prior to SARS-CoV-2 infection was associated with 1.70-fold (95% CI 1.25 to 2.30) and 1.35-fold (95% CI 1.01 to 1.79) increase in anti-ancestral and anti-variant Spike antibody levels, respectively (Extended Fig. 3ab). We also evaluated binding antibody against nucleocapsid protein because this assay is not affected by monoclonal antibody use. Similar to nAb, individuals in the S-HT and S-A subgroups had significantly blunted increases in nucleocapsid binding Ab development from acute to post-infection, and significantly lower binding Ab levels compared to NS and nonimmunocompromised groups (Fig. 3e). Longitudinally, binding Ab levels in NS and non-immunocompromised groups plateaued around day 20-25 at a level of 1-1.5 log<sub>10</sub> IU/ml, while S-HT/S-A groups exhibited delayed development to a level below 1 log<sub>10</sub> IU/ml after day 50 (Fig. 3f).

#### T Cell Responses

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

In a recent study, Apostolidis et al. demonstrated elevated spike-specific CD8<sup>+</sup> T cell responses in COVID-19 mRNA vaccinated participants with multiple sclerosis receiving anti-CD20 treatment compared to healthy controls<sup>30</sup>. However, it remains largely unknown if different types and levels of immunosuppression are associated with a similar T cell immunophenotype. To this end, we profiled the T cell effector function using enzyme-linked immunosorbent spot (ELISpot) and antigen-specific proliferation assay for a selected group of participants based on sample availability. The non-immunocompromised group had lower interferon gamma (IFN-y) producing units per million cells upon stimulation at both blood draws (acute infection 0-14 days, and postacute 15-60 days after symptom onset or first positive COVID-19 test) compared to both NS and S-A groups in response to both ancestral and variant-specific Spike peptide pools (Fig. 4a). Individuals in the S-A group tended to have the highest levels of CD4+ and CD8+ T cell proliferation upon spike peptide pool stimulation, especially compared to the S-HT and nonimmunocompromised individuals (Fig. 4bc and Extended Fig. 4). In longitudinal analysis, the S-HT group showed poor functional CD4+ and CD8+ T cell proliferation, despite a comparable IFNy secretion level compared to the non-immunocompromised group (Fig. 4d). In contrast, the S-A group showed robust T cell proliferation over time, in response to both ancestral and variantspecific spike peptide pools compared to all other groups, suggestive of either an antigenstimulated compensatory effect in the setting of B cell deficiency or a medication-related T cell priming.

### **Discussion**

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

Understanding viral and immune control characteristics of COVID-19 infection is crucial to our ability to care for immunocompromised individuals at greatest risk of persistent and severe infection. Moreover, it can guide public health interventions and shed light on vaccine development that protects immunocompromised individuals. In this study, we performed an indepth virologic and immunologic evaluation of a cohort of immunocompromised and nonimmunocompromised individuals. We demonstrated a hierarchy of immunocompromised conditions that increase the risk of delayed viral clearance and SARS-CoV-2 evolution. Furthermore, we identified the varied risk of persistent COVID-19 across immunosuppressive conditions and suppression of both B and T cell responses in those at the highest risk of persistent infection. Specifically, we found that individuals with a history of hematological malignancy and organ transplant demonstrated the greatest delay in viral clearance that may be mediated by suppression of both the B and T cell responses. In contrast, those with B cell immunodeficiency had an intermediate risk of chronic infection in the setting of an immune response showing compensatory heightened levels of SARS-CoV-2-specific T cell function. Our cohort study confirmed findings from prior case reports and case series. In a review by Dioverti et al., the authors summarized cases of persistent COVID-19 lasting from approximately one month to one year<sup>31</sup>. These included a spectrum of immunocompromised hosts from individuals with solid organ transplants, hematological malignancy<sup>14,20,22,23,25,29,32-36</sup>, and autoimmune diseases receiving immunosuppressive therapies. However, immunocompromise is a broad spectrum and, until now it has not been clear which immunosuppressive conditions represent the greatest risk for persistent infection. The results of our study provide critical insight as to the hierarchy of risk for delayed SARS-CoV-2 RNA and culture clearance, and viral evolution. Specifically, we found that demonstrated that individuals with solid organ transplant and hematological malignancy are associated with the longest period

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

of viral RNA and culturable viral shedding, followed by severely immunocompromised participants with autoimmune conditions receiving B-cell depleted therapy and/or those with B cell deficiency. Participants with mild non-severe immunocompromise, such as those with autoimmune diseases receiving anti-tumor necrosis factor (TNF) treatment, had similar viral shedding dynamics to non-immunocompromised participants. There have been several prior case reports of immunosuppressed individuals with chronic COVID-19 and accumulation of viral polymorphisms and drug resistance mutations 13,14,21,27,34, but there has been little in the way of more systematic evaluation of viral evolution. In this study, we used S gene-specific deep sequencing to assess longitudinal viral evolution and diversity. Our results show that severe immunosuppression is associated with increased viral evolution and diversification. In addition, severe immunocompromised hosts had a greater risk of developing treatment-emergent resistance mutations to mAb therapy when compared to nonimmunocompromised group participants. These findings highlight the potential for immunocompromised individuals to serve as a source for SARS-CoV-2 evolution and drug resistance, consistent with isolated reports of immunocompromised hosts implicated in the emergence of highly mutated SARS-CoV-2 variants<sup>13,15,16,24,28,37-40</sup>. It should be noted though that even within the category of severe immunocompromise, participants demonstrated a range of viral diversification and evolution patterns, and additional studies are needed to fully assess the drivers of accelerated viral evolution. Another highlight of our study is our use of in-depth analysis of B and T cell responses, including SARS-CoV-2-specific neutralizing and binding antibody levels, as well as ELISpot and T cell proliferation studies. We noted lower levels of neutralizing antibody against both ancestral virus and variant virus in the severe immunocompromised group (less than 10-20% compared to non-immunocompromised individuals), after adjusting for vaccination doses, monoclonal

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

antibody use, and demographic confounders. Each additional dose of vaccination is associated with an approximately 1.5-fold increase in antibody levels in the whole cohort, underscoring the importance of adherence to COVID-19 vaccination recommendations. However, there is evidence that non-B-cell immunity may be sufficient for the clearance of SARS-CoV-2. Early in the pandemic, cases were reported of individuals with X-linked agammaglobulinemia who developed COVID-19 pneumonia, but subsequently recovered despite a lack of SARS-CoV-2specific immunoglobulins<sup>41</sup>. In our study, the risk of chronic infection was highest in S-HT participants. This group of participants was found to have both suboptimal humoral and cellmediated immune responses. The "near-normal" level of effector ELISpot responses in S-HT individuals, compared to the non-immunocompromised group, is the likely the result of exposure to high levels of SARS-CoV-2 antigen, while the reduced proliferation demonstrates compromised functionality. In contrast, the S-A participants had an even more robust SARS-CoV-2-specific proliferative T-cell responses than the non-immunocompromised group. indicating increased levels of functional SARS-CoV-2-specific CD8+ T cell responses, which was associated with an intermediate risk of chronic infection. These results align with some intriguing reports that individuals receiving anti-CD20 treatment may demonstrate a stronger Tcell responses, in particular more robust activation-induced marker-positive CD8+ T cell responses<sup>30</sup>. We found that both CD8<sup>+</sup> T cell response and CD4<sup>+</sup> T-cell responses, including proliferation in response to both ancestral and variant-specific spike peptides, were more pronounced in S-A group compared to other non-immunocompromised groups. Together with the results from Apostolidis et al.<sup>30</sup>, our results raise the question of whether individuals with B cell deficiencies may have a lower risk of persistent SARS-CoV-2 infection due to preserved T cell function, either as a compensatory mechanism or T cell priming by certain B cell-depleting therapies.

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

and future therapies.

There are several limitations to this study. We included a relatively small number of individuals with malignant hematological conditions or transplant history, and we were able to obtain blood samples from only a subset of the participants to characterize their humoral and T-cell immunity. Larger studies are needed to provide greater precision as to extent of immune defect or immunosuppressive medication that may place patients at the greatest risk of chronic infection and viral evolution. We also did not analyze markers reflecting innate immunity, including soluble inflammatory markers and monocyte phenotypes. Our study focused on virologic and immunologic responses after COVID-19 and it is unclear how these may contribute to persistence and severity of symptoms. Furthermore, we only evaluated Spike-specific humoral and cellular immunity, while immunity targeting other structural or non-structural proteins has been shown to alter disease course<sup>42,43</sup>. In conclusion, in this prospective cohort of well-characterized individuals with acute COVID-19, we demonstrated a correlation between a hierarchy of immunocompromised conditions and SARS-CoV-2 viral shedding, viral evolution, and adaptive immunity. Our results highlight the finding that the risk of chronic SARS-CoV-2 infection is not uniform across immunosuppressive conditions and provide clarity on which immunosuppression conditions predispose to delayed SARS-CoV-2 RNA and culture clearance, and viral evolution. The high risk populations identified in this study may benefit from targeted public health and additional therapeutic interventions. In addition, the results provide further insights on the humoral and cell-mediated immune correlates of viral clearance, which is crucial for the development of improved vaccines

### Methods

### **Participant Enrollment and Sample Collection**

We enrolled participants with a positive COVID-19 test in the Mass General Brigham Medical HealthCare System as part of the POSt-VaccInaTIon Viral CharactEristics Study (POSITIVES) 17.19 in addition to one immunocompromised participant from our previous study. Each participant's medical record was reviewed for demographic data, immunosuppression status, and COVID-19 treatment history by board-certified clinicians. For the POSITIVES study, participants self-collected anterior nasal swabs every 2-3 days to a total of 6 samples over 2 weeks. Participants with immunocompromised conditions were offered to collect additional swabs when possible and were followed until they had two consecutive negative PCR tests. For this one immunocompromised participants reported previously 13, nasopharyngeal swab was collected by healthcare providers. In a subset of participants who agreed to provide blood sample, the first blood draw was done generally before day 15 of symptom onset (acute phase) or first positive PCR or antigen test for COVID-19, and second blood draw between 15-60 days after (post-acute phase) (Supplementary Fig. 1). This study was approved by Mass General Brigham Institutional Review Board and all participants have signed informed consent upon entry to the study.

#### Categorization for Immunocompromised Conditions

Immunocompromised participants were further categorized into the following groups: severe immunocompromised participants, which were further categorized into severe-hematological malignancy/transplant patients (S-HT), severe autoimmune patients (S-A, participants with autoimmune condition receiving B-cell targeting agents or B cell deficiency); and non-severe immunocompromised participants (NS). This categorization was based on a recent cohort study which demonstrated a hierarchy of antibody response to COVID-19 vaccinations in different medical conditions<sup>4,44</sup>. Detailed classification criteria were listed in Supplemental Table 1.

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

**SARS-CoV-2 Viral Load Assay** SARS-CoV-2 viral RNA (vRNA) were quantified as described previously<sup>45</sup>. Briefly, virions were pelleted from nasal swab fluid by centrifugation at 21.000g for 2 hours at 4°C. Trizol-LS Reagent (Thermofisher Scientific) was added to the pellet, vortexed, and incubated on ice for 10 minutes. Chloroform was added and the solution was vortexed before centrifugation at 21,000g for 15 minutes at 4°C. RNA was isolated from the aqueous layer by isopropanol precipitation and eluted in DEPC-Treated water (Thermofisher Scientific). SARS-CoV-2 RNA copies were quantified with an in-house viral load assay using the CDC 2019-nCoV N1 primer and probe set (Integrated DNA Technologies). The efficiency of the RNA extraction and RT-qPCR amplification was evaluated by quantifying the RCAS RNA recovered from each sample and the two N1 controls. The importin-8 (IPO8) human housekeeping gene was also amplified and evaluated as a measure of sample collection quality. Samples were run in triplicate wells for N1, and in duplicate wells for RCAS and IPO8. **SARS-CoV-2 Viral Culture Assay** Viral culture was performed as previously reported<sup>17</sup>. Vero-E6 cells (ATCC) maintained in DMEM(Corning) supplemented with HEPES (Corning), 1X Penicillin (100 IU/mL)/Streptomycin (100 µg/ml) (Corning), 1X Glutamine (Glutamax, Thermofisher Scientific) and 10% FBS (MilliporeSigma) were plated 16-20 hours before infection. Each sample consisting of nasal swab fluid was thawed on ice and filtered through a Spin-X 0.45 um filter (Corning) at 10,000 xg for 5 minutes. Before infection the media was changed to DMEM supplemented with HEPES. 1X Antibiotic/Antimycotic (ThermoFisher), 1X Glutamine, 2% FBS and 5 µg/mL of polybrene (Santa Cruz Biotechnologies). Each filtered sample was then used to inoculate Vero-E6 cells by

spinfection (2,000x g for 1 hour at 37C). Each condition was plated in quadruplicate wells in 1:5

dilutions across half the plate. The plates were observed at 7-days post-infection using a light microscope to check for cytopathogenic effect (CPE) and a median tissue culture infectious dose (TCID<sub>50</sub>) was calculated for each sample.

### **Neutralizing Antibody Responses**

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

Neutralizing activity against SARS-CoV-2 pseudovirus was measured using a single-round infection assay in 293T/ACE2 target cells<sup>18</sup>. Pseudotyped virus particles were produced in 293T/17 cells (ATCC) by co-transfection of plasmids encoding codon-optimized full-length Spike (ancestral-D614G, Delta, Omicron-BA.1, Omicron-BA.2, Omicron-BA.4/5), packaging plasmid pCMV ΔR8.2, and luciferase reporter plasmid pHR' CMV-Luc. Packaging and luciferase plasmids were kindly provided by Dr. Barney Graham (NIH, Vaccine Research Center). The 293T cell line stably overexpressing the human ACE2 cell surface receptor protein was kindly provided by Drs. Michael Farzan and Huihui Ma (The Scripps Research Institute). For neutralization assays, serial dilutions of patient sera were performed in duplicate followed by addition of pseudovirus. Pooled serum samples from convalescent COVID-19 patients or prepandemic normal healthy serum (NHS) were used as positive and negative controls, respectively. Plates were incubated for 1 hour at 37°C followed by addition of 293/ACE2 target cells (1x10<sup>4</sup>/well). Wells containing cells + pseudovirus (without sample) or cells alone acted as positive and negative infection controls, respectively. Assays were harvested on day 3 using Promega BrightGlo luciferase reagent and luminescence detected with a Promega GloMax luminometer. Titers are reported as the dilution of serum that inhibited 50% virus infection (ID<sub>50</sub> titer). Pseudovirus-based neutralization assays were conducted using ancestral Spike protein, as well as Delta- and Omicron- (BA.1, BA.2, or BA.4/5) Spike. Anti-variant neutralizing antibody level (nAb) was determined based on the viral strain each participant was infected with (either by sequencing or in small proportion, imputed by time of infection when specific strain was prevalent).

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

**Nucleocapsid binding antibody assay** Binding antibody against Nucleocapsid protein was measured using Coronavirus Ig Total Human 11-Plex ProcartaPlex™ Panel (Thermal Fisher) according to the manufacturer's instruction. T Cell Enzyme-linked immunosorbent spot (ELISpot) Assay Interferon (IFN)-y ELISpot assay was reported in our previous study and were performed according to the manufacturer's instructions (Mabtech)<sup>46</sup>. Briefly, peripheral blood mononuclear cells (PBMCs) were incubated with SARS-CoV-2 peptide pools (MGH Peptide Core) at a final concentration of 0.5µg/ml for 16–18h (100,000-200,000 cells per test). Anti-CD3 (Clone OKT3, Biolegend, 0.5µg/mL) and anti-CD28 Ab (Clone CD28.2, Biolegend, 0.5µg/mL) were used as positive controls. To quantify antigen-specific responses, mean spots of the DMSO negative control wells were subtracted from the positive wells. The results were expressed as spotforming units (SFU) per 10<sup>6</sup> PBMCs. Responses were considered positive if the results were >5 SFU/10<sup>6</sup> PBMCs following control subtraction. If negative DMSO control wells had >30 SFU/10<sup>6</sup> PBMCs or if positive control wells (anti-CD3/anti-CD28 stimulation) did not have >1000 spot-forming units, the results were deemed invalid and excluded from further analysis. T Cell Proliferation Assay T Cell proliferation assay was reported previously<sup>46</sup>. Briefly, PBMCs were incubated in PBS with 0.5 uM carboxyfluorescein succinimidyl ester (CFSE; Life Technologies) or CellTrace™ Far Red (CTFR, Invitrogen) at 37°C for 20 min. Then they were washed and resuspended at 0.5-1 × 106/mL and plated into 96-well U-bottom plates (Corning) in 200 µL of. media. Peptide pools were added at a final concentration of 0.5 µg/mL, followed by incubation at 37°C, 5% CO<sub>2</sub> for six days. The PBMC staining antibody panels are in Supplementary Materials. Cells were washed

and fixed in 2% paraformaldehyde prior to flow cytometric analysis on a BD LSR II (BD Biosciences). A positive proliferation response was defined as a percentage of CD3<sup>+</sup>CD4<sup>+</sup> or CD3<sup>+</sup>CD8<sup>+</sup> CFSE<sup>low</sup> or CTFR<sup>low</sup> cells with at least 1.5x greater than the highest of two negative-control wells and greater than 0.2% CFSE<sup>low</sup> or CTFR<sup>low</sup> cells in magnitude following background subtraction.

### SARS-CoV-2 S-gene Sequencing

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

SARS-CoV-2 viral RNA (vRNA) isolation as described previously<sup>45</sup>. RNA was converted to cDNA using Superscript IV reverse transcriptase (Invitrogen) as per manufacturer's instructions). Spike (S) gene amplification was performed using a nested PCR strategy with in-house designed primer sets targeting codons 1–814 of the Spike as previously described<sup>28</sup>. Further, PCR products from different individuals were pooled, and Illumina library construction was performed using the Nextera XT library prep kit (Illumina). Sequencing was performed on the Illumina MiSeq platform and deep sequencing data analysis was carried out using the Stanford Coronavirus Antiviral & Resistance Database (CoVDB) platform (https://covdb.stanford.edu/sierra/sars2/byreads/?cutoff=0.01&mixrate=0.01)<sup>47</sup>. Input FASTQ sequence alignment with Wuhan-Hu-1 reference was done using MiniMap2 version 2.22 CodFreq pipeline (https://github.com/hivdb/codfreq). The output of MiniMap2, an aligned SAM file, is converted to a CodFreq file by an in-house written Python script using a PySam library (version: 0.18.0) and further analyzed with the CoVDB. PCR and sequencing runs were performed once with the appropriate positive and negative controls. For S gene analysis, amino acid variants were then called at the codon level using perl code and used for resistance interpretation with a 1% limit of detection. The accuracy of the deep sequencing platforms was evaluated with a control library of clonal SARS-CoV-2 sequences mixed at known concentrations as described previously<sup>48</sup>. Mutations detected by next-generation sequencing at <20% of the viral population were labelled as 'low-frequency' variants as they would largely be missed by traditional Sanger sequencing. A

minimum average of 500x sequencing coverage per sample was required for variant calling. SARS-COV-2 variant calling was done using 3 different variant calling platforms, namely, CoVDB<sup>47</sup>, Scorpio call v1.2.123 (https://pangolin.cog-uk.io/), and Nextclade v.1.13.2 (https://clades.nextstrain.org/)<sup>49</sup>. Mutation locations are graphically represented in heatmap for Spike and in Circos plots for whole genome.

### Single nucleotide variation, and genetic diversity analysis

For assessing intrahost single nucleotide variation (iSNV), data from only those participants were included for whom sequence data from baseline and at least one follow-up time point were available. SNV analysis was performed using PASeq SARS-CoV-2 pipeline (www.paseq.org). Briefly, raw sequence files were quality filtered and adapter-trimmed using trimmomatic (v0.30). Contaminating sequences were filtered out using BBMap Suite (v35.76). Duplicated reads were detected using fastuniq (v1.1). High quality non-redundant reads were then aligned to SARS-CoV-2 Wuhan reference (NC\_045512.2) using Bowtie2 (v.2.3.2). Resulting alignments were processed with samtools (v.1.2) and iVar (v1.4.2) to obtain nucleotide variant VCF files. Nucleotide variants present at 100% frequency of the total viral population at all time points indicative of lineage defining mutations were excluded from the iSNV analysis. Genetic diversity between multiple sequences of an individual were assessed by average pairwise distance in MEGA both at the nucleotide and amino-acid level.

### **Statistical Analysis**

Categorical variables were summarized using total number and percentage and between-group differences were evaluated using either chi-squared test or Fisher's exact test when appropriate. Continuous variables were summarized with median and interquartile ranges and compared with non-parametric methods (Wilcoxon rank-sum test to compare two groups and Dunn's test with Benjamini-Hochberg adjustment to compare three or more groups). Within

group comparison was conducted using paired Wilcoxon signed-rank test without adjustment for multiple comparisons. We also used generalized estimating equation (GEE) with Gaussian estimation to evaluate between-group differences accounting for repeated measurement during longitudinal follow-up. R (4.3.0) was used for statistical analyses. Two-tailed tests were used for all the analyses and P<0.05 was considered statistically significant unless specified otherwise.

### References

- El Sahly, H.M., et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of
  Blinded Phase. N Engl J Med 385, 1774-1785 (2021).
- Moreira, E.D., Jr., *et al.* Safety and Efficacy of a Third Dose of BNT162b2 Covid-19
  Vaccine. *N Engl J Med* 386, 1910-1921 (2022).
- Watson, O.J., et al. Global impact of the first year of COVID-19 vaccination: a
  mathematical modelling study. The Lancet. Infectious diseases 22, 1293-1302 (2022).
- 4. Haidar, G., et al. Prospective Evaluation of Coronavirus Disease 2019 (COVID-19)
- Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the
- 472 COVID-19 Vaccination in the Immunocompromised Study (COVICS). *Clin Infect Dis* **75**, e630-e644 (2022).
- 474 5. Wieske, L., et al. Humoral responses after second and third SARS-CoV-2 vaccination in
- patients with immune-mediated inflammatory disorders on immunosuppressants: a
- 476 cohort study. The Lancet. Rheumatology 4, e338-e350 (2022).
- 477 6. Kelly, J.D., et al. Incidence of Severe COVID-19 Illness Following Vaccination and
- 478 Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines. *Jama* **328**, 1427-
- 479 1437 (2022).
- 480 7. Agrawal, U., et al. Severe COVID-19 outcomes after full vaccination of primary schedule
- and initial boosters: pooled analysis of national prospective cohort studies of 30 million
- individuals in England, Northern Ireland, Scotland, and Wales. Lancet (London, England)
- **483 400**, 1305-1320 (2022).
- 484 8. Planas, D., et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody
- 485 neutralization. *Nature* **596**, 276-280 (2021).
- 486 9. Hoffmann, M., et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and
- 487 evades antibodies induced by infection and vaccination. *Cell Reports* **36**(2021).
- 488 10. Wang, Q., et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4
- 489 and BA.5. *Nature* **608**, 603-608 (2022).
- 490 11. Weigang, S., et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed
- 491 COVID-19 patient as a source of immune escape variants. *Nat Commun* **12**, 6405
- 492 (2021).
- 493 12. Cele, S., et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves
- 494 extensive immune escape. *Cell Host Microbe* **30**, 154-162 e155 (2022).
- 495 13. Choi, B., et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised
- 496 Host. N Engl J Med **383**, 2291-2293 (2020).

- 497 14. Hensley, M.K., et al. Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged
- 498 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a
- 499 Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. Clin Infect
- 500 Dis **73**, e815-e821 (2021).
- 501 15. Harari, S., et al. Drivers of adaptive evolution during chronic SARS-CoV-2 infections. Nat
- 502 *Med* **28**, 1501-1508 (2022).
- 503 16. Choudhary, M.C., Crain, C.R., Qiu, X., Hanage, W. & Li, J.Z. Severe Acute Respiratory
- 504 Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus
- Disease 2019 (COVID-19) Persistence and Reinfection. *Clin Infect Dis* **74**, 237-245
- 506 (2022).
- 507 17. Boucau, J., et al. Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron
- 508 (BA.1) Infection. *N Engl J Med* **387**, 275-277 (2022).
- 509 18. Seaman, M.S., et al. Vaccine breakthrough infection leads to distinct profiles of
- 510 neutralizing antibody responses by SARS-CoV-2 variant. *JCI Insight* **7**(2022).
- 511 19. Siedner, M.J., et al. Duration of viral shedding and culture positivity with postvaccination
- 512 SARS-CoV-2 delta variant infections. *JCI Insight* **7**(2022).
- 513 20. Avanzato, V.A., et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an
- Asymptomatic Immunocompromised Individual with Cancer. *Cell* **183**, 1901-1912.e1909
- 515 (2020).
- 516 21. Chaguza, C., et al. Accelerated SARS-CoV-2 intrahost evolution leading to distinct
- genotypes during chronic infection. *Cell reports. Medicine* **4**, 100943 (2023).
- 518 22. Bailly, B., et al. Persistent Coronavirus Disease 2019 (COVID-19) in an
- 519 Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus
- 520 2 (SARS-CoV-2)-Specific Monoclonal Antibodies. Clin Infect Dis 74, 1706-1707 (2022).
- 521 23. Truffot, A., et al. SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody
- Monotherapy. *Emerging infectious diseases* **27**, 2725-2728 (2021).
- 523 24. Gupta, A., et al. Host immunological responses facilitate development of SARS-CoV-2
- 524 mutations in patients receiving monoclonal antibody treatments. *The Journal of clinical*
- 525 *investigation* **133**(2023).
- 526 25. Baang, J.H., et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2
- 527 Replication in an Immunocompromised Patient. *J Infect Dis* **223**, 23-27 (2021).
- 528 26. Bronstein, Y., et al. Evolution of spike mutations following antibody treatment in two
- immunocompromised patients with persistent COVID-19 infection. *Journal of medical*
- *virology* **94**, 1241-1245 (2022).

- 531 27. Gonzalez-Reiche, A.S., et al. Sequential intrahost evolution and onward transmission of
- 532 SARS-CoV-2 variants. *Nat Commun* **14**, 3235 (2023).
- 533 28. Choudhary, M.C., et al. Emergence of SARS-CoV-2 escape mutations during
- Bamlanivimab therapy in a phase II randomized clinical trial. *Nature microbiology* **7**,
- 535 1906-1917 (2022).
- 536 29. Kemp, S.A., et al. SARS-CoV-2 evolution during treatment of chronic infection. *Nature*
- **592**, 277-282 (2021).
- 538 30. Apostolidis, S.A., et al. Cellular and humoral immune responses following SARS-CoV-2
- 539 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med* 27,
- 540 1990-2001 (2021).
- 541 31. Dioverti, V., Salto-Alejandre, S. & Haidar, G. Immunocompromised Patients with
- Protracted COVID-19: a Review of "Long Persisters". Current transplantation reports, 1-
- 543 10 (2022).
- 32. Nussenblatt, V., et al. Yearlong COVID-19 Infection Reveals Within-Host Evolution of
- SARS-CoV-2 in a Patient With B-Cell Depletion. *J Infect Dis* **225**, 1118-1123 (2022).
- 33. Aydillo, T., et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for
- 547 Cancer. N Engl J Med 383, 2586-2588 (2020).
- 548 34. Gandhi, S., et al. De novo emergence of a remdesivir resistance mutation during
- treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case
- 550 report. *Nat Commun* **13**, 1547 (2022).
- 551 35. Gordon, C.L., et al. Defective Severe Acute Respiratory Syndrome Coronavirus 2
- 552 Immune Responses in an Immunocompromised Individual With Prolonged Viral
- 553 Replication. Open forum infectious diseases 8, ofab359 (2021).
- 36. Monrad, I., et al. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- in Immunocompromised Host Displaying Treatment Induced Viral Evolution. *Open forum*
- infectious diseases **8**, ofab295 (2021).
- 557 37. Braun, K.M., et al. Acute SARS-CoV-2 infections harbor limited within-host diversity and
- transmit via tight transmission bottlenecks. *PLoS pathogens* **17**, e1009849 (2021).
- 559 38. Ko, K.K.K., et al. Emergence of SARS-CoV-2 Spike Mutations during Prolonged
- Infection in Immunocompromised Hosts. *Microbiology spectrum* **10**, e0079122 (2022).
- 561 39. Lythgoe, K.A., et al. SARS-CoV-2 within-host diversity and transmission. Science (New
- 562 York, N.Y.) **372**(2021).
- 563 40. Valesano, A.L., et al. Temporal dynamics of SARS-CoV-2 mutation accumulation within
- and across infected hosts. *PLoS Pathog* **17**, e1009499 (2021).

- 565 41. Soresina, A., et al. Two X-linked agammaglobulinemia patients develop pneumonia as
- 566 COVID-19 manifestation but recover. *Pediatric allergy and immunology : official*
- 567 publication of the European Society of Pediatric Allergy and Immunology **31**, 565-569
- 568 (2020).
- 569 42. Dangi, T., et al. Improved control of SARS-CoV-2 by treatment with nucleocapsid-
- specific monoclonal antibody. *The Journal of clinical investigation*, e162282 [Online
- 571 ahead of print] (2022).
- 572 43. Kundu, R., et al. Cross-reactive memory T cells associate with protection against SARS-
- 573 CoV-2 infection in COVID-19 contacts. *Nat Commun* **13**, 80 (2022).
- 574 44. Maneikis, K., et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and
- early clinical outcomes in patients with haematological malignancies in Lithuania: a
- 576 national prospective cohort study. *The Lancet Haematology* **8**, e583-e592 (2021).
- 577 45. Fajnzylber, J., et al. SARS-CoV-2 viral load is associated with increased disease
- severity and mortality. *Nat Commun* **11**, 5493 (2020).
- 579 46. Nathan, A., et al. Structure-guided T cell vaccine design for SARS-CoV-2 variants and
- 580 sarbecoviruses. *Cell* **184**, 4401-4413.e4410 (2021).
- 581 47. Tzou, P.L., Tao, K., Pond, S.L.K. & Shafer, R.W. Coronavirus Resistance Database
- 582 (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma,
- and plasma from vaccinated persons. *PloS one* **17**, e0261045 (2022).
- 584 48. Li, J.Z., et al. Impact of pre-existing drug resistance on risk of virological failure in South
- Africa. The Journal of antimicrobial chemotherapy **76**, 1558-1563 (2021).
- 586 49. Aksamentov, I., Roemer, C., Hodcroft, E.B. & Neher, R.A. Nextclade: clade assignment,
- 587 mutation calling andquality control for viral genomes. The Journal of Open Source
- 588 Software **6**, 3773 (2021).

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

Figure Legends Figure 1. Kinetics of SARS-CoV-2 viral RNA and culturable virus among different immunocompromised groups. a, Upper respiratory viral load decay. Lower level of quantification (LLOQ) is 10 copies/ml. b, Kaplan-Meier estimates of upper respiratory viral clearance (viral load below LLOQ). c, Upper respiratory culturable virus dynamics (50% Tissue Culture Infectious Dose [TCID50)). d, Kaplan-Meier estimates of upper respiratory culturable virus clearance. Figure 2. SARS-CoV-2 intra-host mutations among different immunocompromise groups. a, Number of intra-host single-nucleotide variants (iSNVs) among severe (S-HT in red and S-A in green), non-severe immunocompromised and non-immunocompromised (None) groups. b, Nucleotide average pairwise distance (APD) among severe (S-HT in red and S-A in green). non-severe immunocompromised (NS) and non-immunocompromised (None) groups. c, Participants with any nucleotide changes during follow-up. d, Heat map showing distribution of Spike polymorphisms from participants receiving mAb treatment. Each row represents one participant, while x axis shows amino acid positions in the Spike gene. Different domains of Spike are shown at the top. Colors indicate frequency of polymorphisms, with blue indicating the lowest value and red indicating the highest value in the scale. Participants in different study groups are separated by a red horizontal line. e, Proportion of mAb resistance emergence amongst those treated with mAbs, categorized by those with severe or non-severe/no immunosuppression. Comparison of iSNV and APD between groups were done using using Dunn's test with Benjamini-Hochberg P value adjustment. Fisher's exact test was used to calculate significance between participants with and without viral evolution and further, in participants with and without mAb treatment specific resistance mutations. Only significant P values are shown. NTD, N-terminal domain; RBD, receptor binding domain; RBM, receptor binding motif; S1, subunit 1; S2, subunit 2.

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

Figure 3. Neutralizing antibody (nAb) and Nucleocapsid binding antibody levels among different immunocompromised groups. a, nAb levels (50% inhibitory dilution [ID<sub>50</sub>]) against ancestral Spike protein. **b**, nAb levels against variant-specific Spike protein. **c** and **d**, Longitudinal trajectory of nAb in different immunocompromise groups, including (c) or excluding (d) monoclonal antibody use. e, binding antibody levels against Nucleocapsid protein. f, Longitudinal trajectory of binding antibody in different immunocompromise groups. Comparison between different immunocompromise groups at the same time point was performed using Dunn's test with Benjamini-Hochberg P value adjustment. Comparison of longitudinal antibody changes for participants with two blood draws was performed using the pairwise Wilcoxon rank sum test with Benjamini-Hochberg P value adjustment. Only significant P values were shown. Tukey boxplot was used to summarize antibody levels. Generalized additive model was used to evaluate the trend of antibody development with 95% confidence intervals in the shaded area. Lines between two timepoints indicate the same participants with two blood draws. S-HT, severe hematologic-oncology/transplant; S-A, severe autoimmune/B-cell deficient; NS, nonsevere. Severe group included both S-HT and S-A as they had comparable antibody levels at multiple time points. Figure 4. Spike-specific T levels among different immunocompromised groups. a, enzyme-linked immunosorbent spot (ELIspot) assays using peptide pools derived from ancestral and variant-specific Spike protein. **b**, **c**, CD4<sup>+</sup> T cell (b) and CD8<sup>+</sup> T cell proliferation (c) upon stimulation of ancestral- and variant-specific Spike peptide pools. d, Longitudinal trajectory of Spike-specific T levels in different immunocompromise groups. Comparison between different immunocompromise groups at the same time point was performed using Dunn's test with Benjamini-Hochberg P value adjustment. Comparison of longitudinal antibody changes for participants with two blood draws was performed using the pairwise Wilcoxon rank

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

sum test with Benjamini-Hochberg P value adjustment. Only significant P values were shown. Tukey boxplot was used to summarize antibody levels. Generalized additive model was used to evaluate the trend of antibody development with 95% confidence intervals in the shade area. Lines between two timepoints indicate the same participants with two blood draws. Extended Figure 1. Detectable SARS-CoV-2 viral RNA (a) and culturable SARS-CoV-2 virus (b) beyond 30 days after symptom onset or first positive PCR/antigen tests, **supplemental to Fig. 1**. Fisher's exact test was used to calculate the P values. **Extended Figure 2. a**, SARS-CoV-2 intrahost mutations at the amino acid level among different immunocompromise groups. b, Heat map showing distribution of Spike polymorphisms from participants receiving mAb treatment longitudinally, supplemental to Fig. 2. In the heatmap, y axis indicates participants' ID (PID) followed by sequential numbers of sample collection, while x axis shows amino acid positions in the Spike gene. Different domains of Spike are shown at the top. Colors indicate frequency of polymorphisms, with blue indicating the lowest value and red indicating the highest value in the scale. Participants in different study groups are separated by a red horizontal line. mAb resistance mutations are shown by red dotted box. Extended Figure 3. Severe immunocompromise is associated with lower neutralizing antibody levels, supplemental to Fig. 3. Generalized estimation equation to account for longitudinal repeated measurements was used to estimate the association between immunocompromise groups and neutralizing antibody levels against ancestral SARS-CoV-2 Spike protein (a) and variant-specific Spike protein (b). Monoclonal antibody (mAb) use, weeks since symptom onset or first positive PCR/antigen, numbers of vaccinations before enrollment, sex, and age were adjusted for in these models.

**Extended Figure 4. Representative T cell proliferation assay gating scheme, supplemental to Fig. 4.** CD4<sup>+</sup> and CD8<sup>+</sup> T cell proliferation results from representative participants in each immunocompromise group are shown. Non-immunocompromised group, ID=261 (Omicron, BA.1); Non-severe group (NS), ID= 768 (Omicron, BF.5); Severe-autoimmune/B-cell deficient (S-A), ID=534 (Omicron, BA.2); Severe-hematological malignancy/transplant (S-HT), ID= 245 (Delta, B.1.617.2).

Table 1. Demographic and clinical information.

	Immunocompromised (N=56)	Non-Immunocompromised (N=184)	Total (N=240)	P value
Sex, n (%)	,	,		0.2
Female	32 (57.1%)	126 (68.5%) 158 (65.8		
Male	24 (42.9%)	58 (31.5%)	82 (34.2%)	
Age, Median (Q1, Q3)	55 (45, 67)	46 (33, 59)	49 (34-60)	0.001
Race, n (%)				0.8
Asian	1 (1.8)	10 (5.4)	11 (4.6)	
Black or AA	5 (8.9)	19 (10.3)	24 (10.0)	
Other/Unknown	5 (8.9)	16 (8.7)	21 (8.8)	
White	45 (80.4)	139 (75.5)	184 (76.7)	
Ethnicity				0.5
Hispanic or Latino	5 (8.9)	17 (9.2)	22 (9.2)	
Not Hispanic or Latino	47 (83.9)	143 (77.7)	190 (79.2)	
Other/Unknown	4 (7.1)	24 (13.0)	28 (11.7)	
Inpatient, n (%)	7 (12.5)	8 (4.3)	15 (6.2)	0.051
Number of vaccinations, median number, (Q1, Q3)	3 (3-4)	3 (2-3)	3 (2-4)	<0.001
mAb use, n (%)	24* (42.9)	10 (5.4)	34 (14.2)	< 0.001
Antiviral use, n (%)	40 (71.4)	57 (31.0)	97 (40.4)	<0.001
Immunocompromise group, n (	nunocompromise group, n (%)			<0.001
S-HT	12 (21.4)	0 (0.0)	12 (5.0)	
S-A	13 (23.2)	0 (0.0)	13 (5.4)	
NS	31 (55.4)	0 (0.0)	31 (12.9)	
None	0 (0.0)	184 (100.0)	184 (76.7)	
Symptom duration, median days** (Q1, Q3)	5 (4, 7)	4 (3, 6)	4 (3, 6)	0.04
Variant***				<0.001
Delta	3 (5.4)	43 (23.4)	46 (19.2)	
Omicron	48 (85.7)	137 (74.5)	185 (77.1)	
Other/Unknown	5 (8.9)	4 (2.2) 9 (3.8)		

Q1 and Q3, quartile 1 and quartile 3; AA, African American; mAb, monoclonal antibody; S-HT, severe with malignant hematology or transplant history; S-A, severe autoimmune/B-cell deficient; NS, non-severe immunocompromising condition.

<sup>\*,</sup> four participants received Mab after blood draws.

<sup>\*\*,</sup> Symptom duration indicates the duration between symptom onset (patient report or first positive test if asymptomatic screening) and first nasal swab collected by the study group.

<sup>\*\*\*,</sup> Variant information was obtained by either Spike or whole genome sequencing or by epidemiological information (time period when the participant was infected).


Table 2. Association between immunocompromise groups and SARS-CoV-2 viral decay.


Hazard ratio for SARS-CoV-2 viral RNA clearance						
Group	HR (95% CI)	Р	aHR (95% CI)	Р		
None (Reference)						
S-HT	0.24 (0.10-0.57)	0.001	0.35 (0.13-0.91)	0.03		
S-A	0.64 (0.34-1.22)	0.2	0.75 (0.34-1.67)	0.5		
NS	0.82 (0.54-1.24)	0.4	0.93 (0.59-1.47)	0.7		
Hazard ratio for SARS-CoV-2 culturable virus clearance						
Group	HR (95% CI)	Р	aHR (95% CI)	Р		
None (Reference)						
S-HT	0.28 (0.14-0.56)	0.0004	0.34 (0.15-0.76)	0.009		
S-A	0.55 (0.29-1.04)	0.07	0.55 (0.27-1.14)	0.1		
NS	1.07 (0.73-1.58)	0.7	1.30 (0.86-1.99)	0.2		


HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval.


Age, sex at birth, race, ethnicity, number of vaccinations, monoclonal use, and antiviral use were adjusted for in the multivariate models.


Fig.1















a ID₅o to Ancestral strain



# b ID₅₀ to Variant strain

